ClinicalTrials.gg
RecruitingNCT05391113RESYSTAAUpdated Nov 9, 2026

REward SYSTem in Autism Spectrum Disorder and Addictive Disorder

An interventional study of MRI and EEG in Autism Spectrum Disorder, sponsored by University Hospital, Tours. Recruiting at 3 sites in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.

Primary conditionAutistic DisorderRegistry: Autism Spectrum DisorderReclassifiedWhy we changed it
Registry
Autism Spectrum Disorder — the first condition term the registry derived for this study.
ClinicalTrials.gg
Autistic Disorder
Why
  1. The study's listed conditions name Autistic Disorder, a narrower term within Autism Spectrum Disorder.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University Hospital, Tours · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 3 months later.
Updated Nov 9, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
78
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Autistic Disorder with a site in France — 10 open to participants now, 10 under way, 1 of them phase 3. Autistic Disorder · France.

Planned enrollment
16th of 37
78 · median 60
Started
2023
with 4 others
No phase
26 of 50
7 open now
Registered
40th of 50
by date
Lead sponsor
5 of 50
University Hospital, Tours

Among the 50 studies in Autistic Disorder with a site in France, this one is the 16th largest by planned enrollment of the 37 interventional ones that give a count, is one of 5 that started in 2023, is one of 26 with no phase, and was the 40th registered.

Autistic Disorder

1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.

Browse Autistic Disorder studies →

Open to participants now

10 of the 50 studies in Autistic Disorder with a site in France are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 184 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 144 (78%) stop at 75 or younger; 150 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Autistic Disorder with a site in France, or all of them as a file.
02

Study summary

An MRI Study in Subjects with Autism Spectrum Disorder and Subjects with Food Addictive Disorder compared to healthy volunteers.

Read the detailed description

An MRI Study in Subjects with Autism Spectrum Disorder and Subjects with Food Addictive Disorder compared to healthy volunteers, where pathophysiology common to both disorders, based on a dysfunction of the reward system. The project we propose aims to explore the neural networks underlying these alterations in patients suffering from autism or addictive disorder.

03

Conditions studied

  • Autism Spectrum Disorder

Browse trials for

Keywords

  • Autism; MRI;Addictive disorders
04

In context

Autistic Disorder Reclassified

1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.

This study's planned enrollment of 78 is above the median of 50 across 814 interventional studies indexed under Autistic Disorder.

Browse Autistic Disorder studies →

Lead sponsor

University Hospital, Tours is the lead sponsor of 309 studies on the registry; 81 are open to participants now.

Compared within Autistic Disorder, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Autism Spectrum Disorder. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Arm A ˗ Concerning ASD patients: Adult carrying the diagnosis of ASD (, ADOS, ADI-R criteria)

Arm B ˗ Concerning FAD patients: Adult diagnosed with FA presenting with food addiction (DSM-5, YFAS 2.0, BES >= 18 criteria).

Arm C ˗ Concerning healthy volunteers : Adult with no neurological and psychiatric history , absence of progressive somatic pathologies or with vital risk.

For all participants:

  • Age greater than or equal to 18 years old
  • Without intellectual delay (IQ > 70).
  • Able to understand and apply the instruction when an active task is proposed, according to the estimate of the investigator.
  • Free, express, informed and written consent of the participant.
  • Participant affiliated to a social security scheme

Exclusion criteria

Exclusion Criteria:

  • Neuromotor disorders.
  • Visual disturbances not corrected or incompatible with MRI.
  • Known epilepsy.
  • Current substance use disorder with emotional distress/significant impact on functional outcome
  • Rare genetic syndrome.
  • to MRI (other than body circumference)
  • For women of childbearing age: negative urine or blood pregnancy test
  • Person subject to a measure of judicial protection (safeguard of justice, curatorship, guardianship or family authorization)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    Autism Spectrum Disorder

    Characterized by two main diagnostic criteria: a socio-emotional deficit via a defect in communication and social reciprocity, and a behavioral deficit which manifests itself in repetitive behavioral patterns (stereotypes), restricted interests and/or activities.

    Diagnostic Test: MRI · Diagnostic Test: EEG

  • Active comparator
    Food Addictive Disorders

    Characterized by regroup substance use disorders and behavioral addictions, are characterized in particular by the repeated occurrence of compulsive behavior and impaired social functioning

    Diagnostic Test: MRI · Diagnostic Test: EEG

  • Placebo comparator
    Healthy volonteers

    Adult without neurological and psychiatric history, absence of progressive somatic pathologies or with vital risk.

    Diagnostic Test: MRI · Diagnostic Test: EEG

Interventions

  • Diagnostic testMRI

    an fMRI measurement of the BOLD physiological signal for sensory responses

    Also known as: Functionnal MRI

  • Diagnostic testEEG

    These tests, through videos with a social or non-social content (human presence or absence on the stereoscopic projection), will allow us to study two types of sensorialities (visual and interoceptive). Thus, it will be possible to obtain inter- and exteroceptive profiles of the participants, a direct reflection of the processing of the internal bodily sensations of the body.

    Also known as: Electro Encephalography

07

What researchers measure

Primary outcomes

  1. Blood Oxygene Level Dependent (BOLD) MRI signal

    Measurement in fMRI of the BOLD signal for each condition (interest, addiction, social) will be carried out in order to highlight the possible alterations of the reward system, in particular at the level of the striatum in terms of cerebral activation for each of the groups of subjects. (FAD, ASD and HV).

    Time frame: At inclusion

Secondary outcomes

  1. Tolerance to an MRI examination for FAD with overweight or obesity

    For the tolerance to an MRI examination for FAD with overweight or obesity: feedback on their experience in MRI.

    Time frame: At inclusion

  2. Regulation of sensory, an fMRI measurement of the BOLD physiological signal for sensory responses (sensory block) in terms of brain activation in patients

    Regulation of sensory, an fMRI measurement of the BOLD physiological signal for sensory responses (sensory block) in terms of brain activation in patients with FAD compared to ASD subjects and healthy volunteers.

    Time frame: At inclusion

08

Study locations

3 of 3 sites recruiting
  • Center-Val de Loire Region Autism Resource Center
    Tours, 37044, France
    Recruiting
    • Emmanuelle HOUY-DURAND, MD-PhD · ContactE.HOUY-DURAND@chu-tours.fr · +3318370545
    • Frédéric BRIEND, PhD · Principal investigator
    • Marianne LATINUS, PhD · Sub investigator
    • Laurent BARANTIN, PhD · Sub investigator
    • Emmanuelle HOUY-DURAND, MD-PhD · Sub investigator
  • University Addictology Service, Liaison Team and Addictology Care
    Tours, 37044, France
    Recruiting
  • University Hospital, Medical Imaging Service
    Tours, 37044, France
    Recruiting
    • Jean-Philippe COTTIER, MD-PhD · Contactcottier@med.univ-tours.fr · +33234379615
    • Jean-Philippe COTTIER, MD-PhD · Sub investigator
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Jul 2028, 60 months after the start.

Of 355 non-industry interventional studies with no phase under Autistic Disorder, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 60 months is above that.

Counting every sponsor, half of 367 studies reached it within 26 months; a quarter within 13 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Jul 2026 → Jul 2028 and completion Jan 2027 → Jul 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2022
First posted
May 25, 2022
StartActual
Jul 27, 2023
Primary completionEst.
Jul 2028was Jul 2026
CompletionEst.
Jul 2028was Jan 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 27, 2026→Jul 2028
Nov 9, 2026
Study completion
Jan 27, 2027→Jul 2028
Nov 9, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Center-Val de Loire Region Autism Resource Center · Tours, FranceContact person changed (no phone or email listed)Contact person changed (no phone or email listed)Contact person changed (no phone or email listed)Contact person changed (no phone or email listed)
  • University Addictology Service, Liaison Team and Addictology Care · Tours, FranceContact person changed (no phone or email listed)
  • University Hospital, Medical Imaging Service · Tours, FranceContact person changed (no phone or email listed)
Nov 9, 2026
Sponsor
Collaborators added: iBrain 'Imaging & Brain' UMR, Université de Tours Inserm U1253; collaborators removed: INSERM UMR-1253, Tours, France
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Primary completion Jul 27, 2026→Jul 2028
    Study completion Jan 27, 2027→Jul 2028
    Sponsor Collaborators added: iBrain 'Imaging & Brain' UMR, Université de Tours Inserm U1253; collaborators removed: INSERM UMR-1253, Tours, France
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Center-Val de Loire Region Autism Resource Center · Tours, FranceContact person changed (no phone or email listed)Contact person changed (no phone or email listed)Contact person changed (no phone or email listed)Contact person changed (no phone or email listed)
    • University Addictology Service, Liaison Team and Addictology Care · Tours, FranceContact person changed (no phone or email listed)
    • University Hospital, Medical Imaging Service · Tours, FranceContact person changed (no phone or email listed)
    + 4 other changes: identifiers, verification date, oversight details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05391113
Collaborators
iBrain 'Imaging & Brain' UMR, Université de Tours Inserm U1253
Responsible party
Sponsor
First posted
May 25, 2022
Start date
Jul 27, 2023
Primary completion
Jul 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Nov 9, 2026

Study contacts

Frédéric BRIEND, PhD
Contact
frederic.briend@univ-tours.fr
+33247478519
Coralie TAILLEBUIS, MSc
Contact
c.taillebuis@chu-tours.fr
+33247473909
Frédéric BRIEND, PhD
principal investigator · University Hospital,Tours -INSERM U1253 iBrain

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion